No association of the MTHFR gene A1298C polymorphism with the risk of prostate cancer: A meta-analysis

Li,Dawei; Tian,Tian; Guo,Chunhui; Ren,Juchao; Yan,Lei; Liu,Hainan; Xu,Zhonghua

doi:10.3892/etm.2012.445

No association of the MTHFR gene A1298C polymorphism with the risk of prostate cancer: A meta-analysis

Authors:
- Dawei Li
- Tian Tian
- Chunhui Guo
- Juchao Ren
- Lei Yan
- Hainan Liu
- Zhonghua Xu
View Affiliations

Affiliations: Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Tuberculosis, Tuberculosis Hospital of Binzhou City, Binzhou, Shandong 251700, P.R. China, Department of Oncology, Tuberculosis Hospital of Binzhou City, Binzhou, Shandong 251700, P.R. China
Published online on: January 4, 2012 https://doi.org/10.3892/etm.2012.445
Pages: 493-498

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Various studies have demonstrated that the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism contributes to the risk of prostate cancer, while other studies have provided conflicting findings. In the present study, we carried out a comprehensive meta-analysis with the aim of determining whether there is a significant association of the MTHFR gene A1298C polymorphism with the susceptibility of prostate cancer. Studies on the MTHFR gene A1298C polymorphism and prostate cancer were retrieved using the electronic PubMed database without any restriction on language through Aug 21, 2011. Data were abstracted by a standardized protocol. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the strength of association. The analyses were conducted with Review Manager software version 4.2. Nine case-control studies were identified, including 2,723 prostate cancer patients and 3,442 controls. Overall, no significant associations were found between the MTHFR gene A1298C polymorphism and prostate cancer (codominant models: CC vs. AA, OR=1.03, 95% CI 0.79-1.34, P=0.84; AC vs. AA, OR=1.04, 95% CI 0.93-1.16, P=0.46; dominant model: AC + CC vs. AA, OR=1.04, 95% CI 0.94-1.15, P=0.48; recessive model: CC vs. AC + AA, OR=1.02, 95% CI 0.76-1.35, P=0.91; allele model: C vs. A, OR=1.04, 95% CI 0.90-1.19, P=0.61). Similarly, in the subgroup analyses by DNA source, ethnicity, control source, pathological stage and Hardy-Weinberg equilibrium, no significant associations were observed. Our meta-analysis suggests that the MTHFR gene A1298C polymorphism is not associated with the risk of prostate cancer.

View Figures

View References

1.	A JemalR SiegelJ XuE WardCancer statistics, 2010CA Cancer J Clin60277300201010.3322/caac.20073
2.	F BrayR SankilaJ FerlayDM ParkinEstimates of cancer incidence and mortality in Europe in 1995Eur J Cancer3899166200210.1016/S0959-8049(01)00350-111750846
3.	AW HsingAP ChokkalingamProstate cancer epidemiologyFront Biosci1113881413200610.2741/1891
4.	KW JungYJ WonS ParkCancer statistics in Korea: incidence, mortality and survival in 2005J Korean Med Sci249951003200910.3346/jkms.2009.24.6.99519949651
5.	JB MasonT LevesqueFolate: effects on carcinogenesis and the potential for cancer chemopreventionOncology101727173619968953590
6.	YI KimFolate and carcinogenesis: evidence, mechanisms, and implicationsJ Nutr Biochem106688199910.1016/S0955-2863(98)00074-615539274
7.	P GoyetteJS SumnerR MilosHuman methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identificationNat Genet7195200199410.1038/ng0694-195
8.	P FrosstHJ BlomR MilosA candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNat Genet10111113199510.1038/ng0595-111
9.	JR DobosyJL RobertsVX FuDF JarrardThe expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasiaJ Urol177822831200710.1016/j.juro.2006.10.06317296351
10.	TM MurphyAS PerryM LawlerThe emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancerEndocr Relat Cancer151125200810.1677/ERC-07-020818310272
11.	P GoyetteA PaiR MilosGene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR)Mamm Genome9652656199810.1007/s0033599008389680386
12.	M KurzawskiK DziewanowskiK KędzierskaA WajdaJ LapczukM DroździkAssociation of transcription factor 7-like 2 (TCF7L2) gene polymorphism with posttrans-plant diabetes mellitus in kidney transplant patients medicated with tacrolimusPharmacol Rep63826833201110.1016/S1734-1140(11)70595-3
13.	JD LeuCY WangHY TsaiIF LinRC ChenYJ LeeInvolvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancerOncol Rep2517551763201121479369
14.	JW KimHM ParkYK ChoiSY ChongD OhNK KimPolymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patientsOncol Rep25167172201121109973
15.	MM FungRM SalemMS LipkowitzMethylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC)Nephrol Dial TransplantMay2011(E-pub ahead of print)
16.	S DayakarKI GoudTP ReddySP RaoSB SesikeranM SadhnaniSequence variation of the methylene tetrahydrofolate reductase gene (677C>T and 1298 A>C) and traditional risk factors in a South Indian populationGenet Test Mol BiomarkersJuly2011(E-pub ahead of print)
17.	K SiemianowiczJ GminskiW GarczorzMethylenetetrahydrofolate reductase gene C677T and A1298C poly morphisms in patients with small cell and non-small cell lung cancerOncol Rep1013411344200312883704
18.	H ShenAS NewmannZ HuMethylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in ChinaOncol Rep13355360200515643524
19.	MS CicekNL NockL LiDV ContiG CaseyJS WitteRelationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressivenessCancer Epidemiol Biomarkers Prev1313311336200415298954
20.	R SingalL FerdinandPM DasIM ReisJJ SchlesselmanPolymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer riskInt J Oncol2514651471200415492840
21.	BR Van GuelpenSM WirénAR BerghG HallmansPE StattinJ HultdinPolymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case-control studyEur J Cancer Prev154650200616374229
22.	C MarchalM RedondoA Reyes-EngelAssociation between polymorphisms of folate-metabolizing enzymes and risk of prostate cancerEur J Surg Oncol34805810200810.1016/j.ejso.2007.09.00817967524
23.	VL StevensC RodriguezJ SunJT TalbotMJ ThunEE CalleNo association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer riskCancer Epidemiol Biomarkers Prev1736123614200810.1158/1055-9965.EPI-08-078919064578
24.	MH MuslumanogluE TepeliS DemirThe analysis of the relationship between A1298C and C677T polymorphisms of the MTHFR gene with prostate cancer in Eskisehir populationGenet Test Mol Biomarkers13641645200910.1089/gtmb.2009.004619814618
25.	D CaiL NingC PanAssociation of polymorphisms in folate metabolic genes and prostate cancer risk: a case-control study in a Chinese populationJ Genet89263267201010.1007/s12041-010-0037-720861582
26.	MR SafarinejadN ShafieiS SafarinejadRelationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case-control studyProstate7016451657201010.1002/pros.21200
27.	HC WuCH ChangRY TsaiSignificant association of methylenetetrahydrofolate reductase single nucleotide polymorphisms with prostate cancer susceptibility in TaiwanAnticancer Res30357335772010
28.	IS WeisbergPF JacquesJ SelhubThe 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteineAtherosclerosis1564094152001
29.	NM van der PutF GabreëlsEM StevensA second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?Am J Hum Genet621044105119989545395
30.	JL BaiMH ZhengX XiaM Ter-MinassianYP ChenF ChenMTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: a meta-analysis of 3511 cases and 2762 controlsEur J Cancer4514431449200910.1016/j.ejca.2009.01.02019223177
31.	SM CollinC MetcalfeL ZuccoloAssociation of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysisCancer Epidemiol Biomarkers Prev1825282539200910.1158/1055-9965.EPI-09-022319706844
32.	X DongJ WuP LiangJ LiL YuanX LiuMethylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysisArch Med Res41125133201010.1016/j.arcmed.2010.01.00120470942
33.	LX QiuJ ZhangWH LiLack of association between me thylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibilityMol Biol Rep3822952299201110.1007/s11033-010-0361-221052845
34.	B WeiZ XuJ RuanMTHFR 677C>T and 1298A>C polymorphisms and male infertility risk: a meta-analysisMol Biol RepJune2011(E-pub ahead of print)
35.	JN HirschhornK LohmuellerE ByrneK HirschhornA comprehensive review of genetic association studiesGenet Med44561200210.1097/00125817-200203000-00002
36.	KJ LieversGH BoersP VerhoefA second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease riskJ Mol Med (Berl)79522528200110.1007/s001090100253